Company Description
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems...
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.
Valuation
Price to Sales Ratio
1.65
Price to Book Ratio
1.81
Enterprise Value to EBITDA
25.06
Enterprise Value to Sales
2.65
Total Debt to Enterprise Value
0.33
Efficiency
Revenue/Employee
156,977.00
Income Per Employee
-5,123.00
Receivables Turnover
13.58
Total Asset Turnover
0.71
Liquidity
Current Ratio
2.49
Quick Ratio
1.09
Cash Ratio
0.43
Profitability
Gross Margin
29.11
Operating Margin
-0.67
Pretax Margin
-5.03
Net Margin
-3.26
Return on Assets
-2.32
Return on Equity
-4.01
Return on Total Capital
-0.55
Return on Invested Capital
-2.74
Capital Structure
Total Debt to Total Equity
83.02
Total Debt to Total Capital
45.36
Total Debt to Total Assets
38.42
Long-Term Debt to Equity
80.69
Long-Term Debt to Total Capital
44.09
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Vivek Jain | 47 | 2014 | Chairman & Chief Executive Officer |
Mr. Christian Voigtlander | 51 | 2017 | Vice President-Business Development |
Mr. Brian M. Bonnell | - | 2018 | Vice President-Finance |
Mr. Krishna Uppugonduri | - | 2015 | VP-Quality, Medical & Regulatory Affairs |
Mr. Daniel Woolson | 43 | 2017 | Vice President & General Manager-Infusion Systems |
Insider Actions
04/11/2023 |
Virginia Sanzone VP, General Counsel |
250 | Disposition at $175 per share. | 43,750 |
04/05/2023 |
Virginia Sanzone VP, General Counsel |
458 | Disposition at $170 per share. | 77,860 |
03/08/2023 |
Vivek Jain Chairman and CEO; Director |
1,329 | Derivative/Non-derivative trans. at $156.17 per share. | 207,549 |
03/08/2023 |
Christian B. Voigtlander Chief Operating Officer |
1,163 | Derivative/Non-derivative trans. at $156.17 per share. | 181,625 |
03/08/2023 |
Brian M. Bonnell Chief Financial Officer |
1,163 | Derivative/Non-derivative trans. at $156.17 per share. | 181,625 |
03/08/2023 |
Daniel Woolson VP, GM-Infusion Capital |
894 | Derivative/Non-derivative trans. at $156.17 per share. | 139,615 |
03/08/2023 |
Virginia Sanzone VP, General Counsel |
1,196 | Derivative/Non-derivative trans. at $156.17 per share. | 186,779 |
03/08/2023 |
Vivek Jain Chairman and CEO; Director |
2,525 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2023 |
Christian B. Voigtlander Chief Operating Officer |
2,209 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2023 |
Brian M. Bonnell Chief Financial Officer |
2,209 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2023 |
Daniel Woolson VP, GM-Infusion Capital |
2,020 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/08/2023 |
Virginia Sanzone VP, General Counsel |
2,272 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/07/2023 |
Vivek Jain Chairman and CEO; Director |
1,694 | Derivative/Non-derivative trans. at $157.47 per share. | 266,754 |
03/07/2023 |
Christian B. Voigtlander Chief Operating Officer |
1,129 | Derivative/Non-derivative trans. at $157.47 per share. | 177,783 |
03/07/2023 |
Brian M. Bonnell Chief Financial Officer |
1,129 | Derivative/Non-derivative trans. at $157.47 per share. | 177,783 |
03/07/2023 |
Daniel Woolson VP, GM-Infusion Capital |
428 | Derivative/Non-derivative trans. at $157.47 per share. | 67,397 |
03/07/2023 |
Virginia Sanzone VP, General Counsel |
564 | Derivative/Non-derivative trans. at $157.47 per share. | 88,813 |
03/07/2023 |
Vivek Jain Chairman and CEO; Director |
3,218 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/07/2023 |
Christian B. Voigtlander Chief Operating Officer |
2,145 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/07/2023 |
Brian M. Bonnell Chief Financial Officer |
2,145 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/07/2023 |
Daniel Woolson VP, GM-Infusion Capital |
965 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/07/2023 |
Virginia Sanzone VP, General Counsel |
1,072 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Vivek Jain Chairman and CEO; Director |
5,261 | Derivative/Non-derivative trans. at $161.25 per share. | 848,336 |
03/06/2023 |
Vivek Jain Chairman and CEO; Director |
933 | Derivative/Non-derivative trans. at $161.25 per share. | 150,446 |
03/06/2023 |
Christian B. Voigtlander Chief Operating Officer |
816 | Derivative/Non-derivative trans. at $161.25 per share. | 131,580 |
03/06/2023 |
Christian B. Voigtlander Chief Operating Officer |
4,604 | Derivative/Non-derivative trans. at $161.25 per share. | 742,395 |
03/06/2023 |
Brian M. Bonnell Chief Financial Officer |
4,604 | Derivative/Non-derivative trans. at $161.25 per share. | 742,395 |
03/06/2023 |
Brian M. Bonnell Chief Financial Officer |
816 | Derivative/Non-derivative trans. at $161.25 per share. | 131,580 |
03/06/2023 |
Daniel Woolson VP, GM-Infusion Capital |
626 | Derivative/Non-derivative trans. at $161.25 per share. | 100,942 |
03/06/2023 |
Virginia Sanzone VP, General Counsel |
839 | Derivative/Non-derivative trans. at $161.25 per share. | 135,288 |
03/06/2023 |
Vivek Jain Chairman and CEO; Director |
9,994 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Vivek Jain Chairman and CEO; Director |
1,773 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Christian B. Voigtlander Chief Operating Officer |
1,551 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Christian B. Voigtlander Chief Operating Officer |
8,745 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Brian M. Bonnell Chief Financial Officer |
8,745 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Brian M. Bonnell Chief Financial Officer |
1,551 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Daniel Woolson VP, GM-Infusion Capital |
1,417 | Derivative/Non-derivative trans. at $0 per share. | 0 |
03/06/2023 |
Virginia Sanzone VP, General Counsel |
1,595 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/02/2023 |
Daniel Woolson VP, GM-Infusion Capital |
1,731 | Disposition at $200 per share. | 346,200 |
11/15/2022 |
Virginia Sanzone VP, General Counsel |
325 | Disposition at $160.12 per share. | 52,039 |
09/21/2022 |
George A. Lopez Director |
79,576 | Derivative/Non-derivative trans. at $61.76 per share. | 4,914,613 |
05/23/2022 |
Vivek Jain Chairman and CEO; Director |
30 | Gift at $0 per share. | 0 |
05/13/2022 |
Elisha Wade Finney Director |
743 | Gift at $0 per share. | 0 |
MarketWatch News on ICUI
-
Edwards Lifesciences Corp. stock rises Friday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Friday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Tuesday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
ICU Medical downgraded to market perform from outperform at Raymond James
- Tomi Kilgore
-
Edwards Lifesciences Corp. stock falls Friday, still outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, still outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Friday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market despite losses on the day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Monday, outperforms market
- MarketWatch Automation
- Loading more headlines...
Other News on ICUI
-
- Edgar Online - (EDG = 10Q, 10K)
-
ICU Medical, Inc. (ICUI) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
New Strong Sell Stocks for September 8th
- Zacks.com
-
New Strong Sell Stocks for August 11th
- Zacks.com
-
- Edgar Online - (EDG = 10Q, 10K)
-
Top 5 2nd Quarter Trades of Eos Focused Equity Management, L.P.
- GuruFocus.com